Yes, dose effect and tolerability. As for a "ceiling", that can only be effectively determined in a trial or trial phase where you titrate to MTD. We've explored MTD in the Phase 1 and to some extent in the AD phase 2A. It currently stands at a proposed 55mg.
(Need to keep in mind that a well-established MTD is a concept, and an average. Some individuals can tolerate more, some less.)
Market Data 
Markets 
AI
